In this study, our aim is to determine an active but tolerable sublingual dose (range 100 to 4000 µg) of Salvinorin A (SA) in experienced subjects. This study is an ascending-dose, placebo-controlled, single-site design in 8 Salvia-experienced subjects. Subjects will receive SA doses from 0-4000 µg. Doses will be separated by at least one day. The first two doses (0 and 100µg) will be double-blinded while the last four (250, 500, 1000, 2000 and 4000µg) will be single-blind.
Topic Healthy Subjects
Compound Placebo
Salvia Divinorum
Country United States of America
Visit trial
Status
Completed
Results Published
Start date
06 January 2009
End date
10 January 2010
Chance of happening
100%
Phase
Not Applicable
Design
Blinded
Type
Interventional
Generation
First
Participants
8
Sex
All
Age
21- 45
Therapy
No
Trial Details
In this study, our aim is to determine an active but tolerable sublingual dose (range 100 to 4000 µg) of Salvinorin A (SA) in experienced subjects. This study is an ascending-dose, placebo-controlled, single-site design in 8 Salvia-experienced subjects. Subjects will receive SA doses from 0-4000 µg. Doses will be separated by at least one day. The first two doses (0 and 100µg) will be double-blinded while the last four (250, 500, 1000, 2000 and 4000µg) will be single-blind.NCT Number NCT01149824
Sponsors & Collaborators
California Pacific Medical Center Research InstituteThis company doesn't have a full profile yet, it is linked to a clinical trial.